EU Clinical Trial 2018-001926-25

A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis  May 27, 2019

Main objective of the trial: 1. Assess whether BMS-986165 is superior to placebo at Week 16 in the treatment of subjects with moderate-to-severe plaque psoriasis Évaluer si le BMS-986165 est supérieur au placebo à la semaine 16 pour le traitement de sujets atteints de psoriasis en plaques modéré à sévère

Parties

Sponsors
Countries
CA DE ES EU FR GB JP KR NL NO PL RU TW US
Keywords
Apremilast BMS-986165 Otezla 30 mg Plaque psoriasis

JSON preview

Similar records

Title

Source:  EMA Last updated:  May 30, 2019

From ClinicalTrialsRegister.eu, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.